Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Scott

Showing results (331-340 of 360) with videos related to

Pageof 36
Sort By:
The Lancet. Oncology|May 31, 2026
Cancer workforce-a global crisis: a Lancet Oncology CommissionHedvig Hricak, Zachary J Ward, Fabio Ynoe Moraes, et al.
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Molecular Cancer Therapeutics|February 28, 2018
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
The Lancet. Oncology|January 5, 2024
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO groupNathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsAndrew M Scott, Fook-Thean Lee, Niall Tebbutt, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastomaHui K Gan, Lawrence Cher, Po-Ling Inglis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Assessment of Simplified Methods for Quantification of <sup>18</sup>F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate CancerGerbrand M Kramer, Maqsood Yaqub, Herbert A Vargas, et al.
BMJ Open|May 15, 2023
LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot studyBenjamin Y Kong, Hao-Wen Sim, Anna K Nowak, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2004
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humansIan D Davis, Weisan Chen, Heather Jackson, et al.
Pageof 36

Showing results (331-340 of 360) with videos related to

Sort By:
Pageof 36
The Lancet. Oncology|May 31, 2026
Cancer workforce-a global crisis: a Lancet Oncology CommissionHedvig Hricak, Zachary J Ward, Fabio Ynoe Moraes, et al.
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Molecular Cancer Therapeutics|February 28, 2018
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
The Lancet. Oncology|January 5, 2024
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO groupNathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsAndrew M Scott, Fook-Thean Lee, Niall Tebbutt, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastomaHui K Gan, Lawrence Cher, Po-Ling Inglis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Assessment of Simplified Methods for Quantification of <sup>18</sup>F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate CancerGerbrand M Kramer, Maqsood Yaqub, Herbert A Vargas, et al.
BMJ Open|May 15, 2023
LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot studyBenjamin Y Kong, Hao-Wen Sim, Anna K Nowak, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2004
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humansIan D Davis, Weisan Chen, Heather Jackson, et al.
Pageof 36